A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy

BACKGROUND: Autologous NK cell therapy can treat a variety of malignancies, but is limited by patient-specific variations in potency and cell number expansion. In contrast, allogeneic NK cell lines can overcome many of these limitations. Cells from the permanent NK-92 line are constitutively activat...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Brent A., Law, Arjun Datt, Routy, Bertrand, denHollander, Neal, Gupta, Vikas, Wang, Xing-Hua, Chaboureau, Amélie, Viswanathan, Sowmya, Keating, Armand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687687/
https://www.ncbi.nlm.nih.gov/pubmed/29179517
http://dx.doi.org/10.18632/oncotarget.19204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687687/
https://www.ncbi.nlm.nih.gov/pubmed/29179517
http://dx.doi.org/10.18632/oncotarget.19204

Ejemplares similares